Use of compounds for the elevation of pyruvate dehydrogenase activity
申请人:AstraZeneca AB
公开号:US06498275B1
公开(公告)日:2002-12-24
The use of compounds of the formula (I), and salts thereof; and pharmaceutically acceptable in vivo cleavable prodrugs of said compound of formula (I); and pharmaceutically acceptable salts of said compound or said prodrugs:
wherein:
Ring C is phenyl or a carbon linked heteroaryl ring substituted as defmed within;
R1 is an ortho substituent as defined within;
n is 1 or 2;
A—B is a linking group as defined within;
R2 and R3 are as defined within;
R4 is hydroxy, hydrogen, halo, amino or methyl; in the manufacture of a medicament for use in the elevation of PDH activity in warm-blooded animals such as humans is described. Pharmaceutical compositions, methods and processes for preparation of compounds of formula (I) are also described.
Phenyl-substituted perfluoroalkanesulfonanilides in which the phenyl rings are linked by sulfur, sulfinyl or sulfonyl and salts thereof in which the rings and the perfluoroalkylsulfonamido nitrogen are optionally substituted. The compounds are active herbicides and some are anti-inflammatory agents and analgesic agents.
An efficient regioselective synthesis of 4-chalcogen-substituted arylamines by FeF3-catalyzed sulfenylation and selenation of arylamines has been developed. In the presence of FeF3 and I2, a variety of arylamines underwent the reaction with disulfides or diselenides to afford the corresponding 4-sulfenyl- or 4-selenenylarylamines in moderate to good yields.
A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.
A method for producing a biaryl compound, comprising reacting an aromatic organic compound with at least one compound selected from the group consisting of aromatic organoboron compounds and boroxine compounds, in the presence of a zero-valent nickel catalyst, phosphine ligand and base.